A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2022-06-25
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-12-21 (study day 170); relationship: Y
severe
assessed
Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-02-16 (study day 227); relationship: not assessed
moderate
assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-04-25 (study day 295); relationship: N
Data queries
No data queries.